Glenn Rich, MD
Endocrinology, Diabetes & Metabolism · Trumbull, CTNPI 1922027259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $177,883 of the $209,843 with a category attached, or 84.8%. 54 manufacturers reported payments, led by Lilly USA, LLC at 59.2% of the total. Reporting peaked in 2023 at $48,946 and has fallen 54.8% since, to $22,141 in 2025. Among endocrinology, diabetes & metabolism clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 890 payments — averaging $235.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$124K
- Novo Nordisk$31K
- Boehringer Ingelheim$31K
- AstraZeneca$13K
- Merck$4K
- Amgen$1K
- plus $5K from 48 others
What the payments were for
- Consulting fees$7,1483%
- Speaking & faculty fees$177,88385%
- Travel & lodging$7,3313%
- Food & beverage$17,1718%
- Education$3100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$209,843 in reported general payments places this provider in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 380 | $415,448 |
| OzempicSemaglutide | 345 | $391,788 |
| TrulicityDulaglutide | 171 | $192,387 |
| MounjaroTirzepatide | 156 | $179,738 |
| FarxigaDapagliflozin Propanediol | 139 | $157,703 |
| JanuviaSitagliptin Phosphate | 102 | $86,321 |
| Tresiba Flextouch U-200Insulin Degludec | 107 | $81,283 |
| RybelsusSemaglutide | 49 | $73,747 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $35,346 |
| EliquisApixaban | 30 | $27,391 |
| ProliaDenosumab | 11 | $19,158 |
| Novolog FlexpenInsulin Aspart | 76 | $17,638 |
| Humalog Kwikpen U-100Insulin Lispro | 43 | $16,108 |
| WegovySemaglutide | 11 | $14,435 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $12,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $31,217 | $479,970405 claims |
| Boehringer IngelheimJardiance, Tradjenta | $30,662 | $424,285395 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $124,127 | $372,125327 claims |
| AstraZenecaFarxiga | $12,738 | $157,703139 claims |
| MerckJanuvia | $4,314 | $86,321102 claims |
| PfizerEliquis | $128 | $27,39130 claims |
| AmgenProlia | $1,413 | $19,15811 claims |
| AbbVieSynthroid | $805 | $8,208119 claims |
| Johnson & JohnsonXarelto | $174 | $7,82014 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $103 | $6,567678 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Trumbull
- Judith CastilloTrumbull$37K
- Jonathan FillmoreTrumbull$12K
- Joseph RosaTrumbull$8K
- Agnieszka GrochowalskaTrumbull$8K
- Erika StrohmayerTrumbull$4K
- Linda WernerTrumbull$3K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.